Jin Medical International Ltd. (ZJYL) Income Statement
ZJYL FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsZJYL revenue and net income
Where ZJYL's revenue goes
FY2025Each bar shows an amount and its share of revenue. ZJYL kept 5.8% of revenue as net income.
ZJYL profit margins
ZJYL growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −12.0% | +2.5% | +5.0% | — |
| Gross profit | −36.4% | −0.8% | +1.9% | — |
| Operating income | −83.3% | −34.2% | −23.7% | — |
| Net income | −67.6% | −23.9% | −11.6% | — |
| EPS (diluted) | +650.0% | 0.0% | +71.9% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ZJYL quarterly EPS vs estimates
Jin Medical International beat the analyst EPS estimate in 2 of the last 2 quarters.
ZJYL income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.7M | $23.5M | $19.8M | $19.2M | $20.8M | $16.2M | $20.4M | $20.9M |
| Cost of revenue | $14.6M | $14.0M | $13.0M | $13.0M | $14.4M | $10.7M | $12.9M | $13.3M |
| Gross profit | $6.0M | $9.5M | $6.8M | $6.2M | $6.4M | $5.5M | $7.5M | $7.7M |
| Research & development | $1.6M | $1.5M | $1.5M | $1.9M | $1.6M | $1.3M | $1.1M | $1.2M |
| Sales, general & admin | $3.9M | $4.4M | $2.4M | $2.2M | $2.2M | $1.9M | $2.0M | $1.7M |
| Total operating expenses | $5.4M | $5.9M | $17.0M | $4.1M | $3.7M | $3.1M | $3.1M | $3.3M |
| Operating income | $608,182 | $3.6M | $2.9M | $2.1M | $2.6M | $2.4M | $4.4M | $4.2M |
| Interest income | $789,070 | $466,524 | $182,682 | $181,605 | — | — | — | — |
| Interest expense | — | — | — | — | $9,492 | $112,404 | $22,846 | — |
| Income before taxes | $1.6M | $4.2M | $3.2M | $2.7M | $2.9M | $2.4M | $4.1M | $4.3M |
| Income taxes | $214,572 | $763,879 | — | $36,111 | $248,641 | $147,154 | $479,629 | $616,880 |
| Net income | $1.2M | $3.7M | $2.9M | $2.7M | $2.6M | $2.2M | $3.6M | $3.7M |
| EBITDA | $958,861 | $4.0M | $3.1M | $3.1M | $3.2M | $2.8M | $4.7M | $4.6M |
| EPS (diluted) | $0.15 | $0.02 | $0.02 | $0.15 | $0.51 | $0.01 | $0.01 | $0.01 |
| Gross margin | 29.2% | 40.4% | 34.2% | 32.3% | 30.6% | 34.0% | 36.9% | 36.6% |
| Operating margin | 2.9% | 15.5% | 14.5% | 11.1% | 12.7% | 14.5% | 21.6% | 20.2% |
| Net margin | 5.8% | 15.6% | 14.5% | 14.1% | 12.7% | 13.6% | 17.9% | 17.6% |
| Jun '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.9M | $10.8M | $4.9M | $9.9M | $4.9M | $12.9M | $6.5M | $10.6M | $5.3M | $9.6M | $4.8M | $10.3M |
| Cost of revenue | $6.5M | $7.2M | $3.7M | $7.3M | $3.7M | $7.1M | $3.6M | $6.8M | $3.4M | $6.3M | $3.1M | $6.6M |
| Gross profit | $2.4M | $3.6M | $1.3M | $2.5M | $1.3M | $5.8M | $2.9M | $3.8M | $1.9M | $3.3M | $1.7M | $3.6M |
| Research & development | $881,726 | $896,817 | $330,443 | $660,886 | $330,443 | $887,680 | $443,840 | $609,646 | $304,823 | $911,860 | $455,930 | $631,034 |
| Sales, general & admin | — | — | $1.1M | $2.2M | $1.1M | $2.5M | $1.2M | $1.9M | $948,724 | $1.2M | $623,149 | $1.1M |
| Total operating expenses | $3.0M | $2.6M | $1.5M | $3.0M | $1.5M | $3.4M | $1.7M | $2.6M | $1.3M | $2.2M | $1.1M | $1.9M |
| Operating income | −$644,453 | $1.1M | −$227,106 | −$454,212 | −$227,106 | $2.4M | $1.2M | $1.2M | $614,619 | $1.1M | $547,902 | $1.8M |
| Interest expense | — | — | — | — | $215,064 | $215,064 | — | — | — | — | — | — |
| Income before taxes | −$305,046 | $1.6M | $14,282 | $28,564 | $14,282 | $2.2M | $1.1M | $2.0M | $1.0M | $1.3M | $625,769 | $2.0M |
| Income taxes | −$96,042 | $195,006 | $9,783 | $19,566 | $9,783 | $454,866 | $227,433 | $309,014 | $154,507 | $139,654 | $69,827 | $204,052 |
| Net income | −$107,735 | $1.3M | −$44,504 | −$89,008 | −$44,504 | $1.9M | $940,917 | $1.8M | $897,047 | $1.1M | $555,941 | $1.8M |
| EBITDA | −$480,542 | $1.2M | −$161,476 | −$264,684 | −$161,476 | $2.6M | $1.3M | $1.3M | $674,642 | $1.4M | $603,620 | $1.9M |
| EPS (diluted) | — | $0.01 | $0.00 | — | $0.01 | — | — | — | — | — | — | — |
| Gross margin | 26.9% | 33.7% | 25.6% | 25.6% | 25.6% | 44.9% | 44.9% | 36.0% | 36.0% | 34.0% | 34.8% | 35.4% |
| Operating margin | −7.2% | 9.8% | −4.6% | −4.6% | −4.6% | 18.6% | 18.6% | 11.6% | 11.6% | 11.5% | 11.5% | 17.3% |
| Net margin | −1.2% | 11.8% | −0.9% | −0.9% | −0.9% | 14.5% | 14.5% | 17.0% | 17.0% | 11.6% | 11.6% | 17.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ZJYL's financial statements (latest annual report filed February 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ZJYL financial results
In fiscal year 2025 (ended September 30, 2025), Jin Medical International reported revenue of $20.7 million, down 12.0% from the year before. It had net income of $1.2 million (down 67.6%), a net profit margin of 5.8%. Diluted earnings per share came to $0.15. Over five years revenue grew at an average rate of 5.0% a year.
See the ZJYL stock overview for the latest quote and news, or the ZJYL chart for price history and technical indicators.
ZJYL income statement FAQ
What is Jin Medical International's annual revenue?
Jin Medical International reported total revenue of $20.7 million for fiscal year 2025, which ended on September 30, 2025. That was down 12.0% from $23.5 million the previous year.
Is Jin Medical International profitable?
Yes. Jin Medical International reported net income of $1.2 million in fiscal 2025, a net profit margin of 5.8%; its operating margin was 2.9%.
What is Jin Medical International's gross margin?
Jin Medical International's gross margin was 29.2% in fiscal 2025: for every $100 of revenue, Jin Medical International kept $29 after the direct cost of its products and services.
How much does Jin Medical International spend on research and development?
Jin Medical International spent $1.6 million on research and development in fiscal 2025, 7.5% of revenue.
How fast is Jin Medical International growing?
Revenue grew 5.0% a year on average over the last five fiscal years, from $16.2 million to $20.7 million.
What are Jin Medical International's earnings per share?
Jin Medical International earned $0.15 per diluted share in fiscal 2025, compared with $0.02 a year earlier.
When does Jin Medical International's fiscal year end?
Jin Medical International's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on February 10, 2026.